• C. Banz-Jansen


Die Hyperandrogenämie wird als die vermehrte Produktion und Ausschüttung von Androgenen definiert. Dabei kann die Klinik, mit der sich die Patientin an uns wendet, sehr vielfältig sein.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amer SA, Banu Z, Li TC, Cooke ID (2002) Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: endocrine and ultrasonographic outcomes. Hum Reprod 17: 2851–2857PubMedCrossRefGoogle Scholar
  2. Andoh K, Mizunuma H, Liu X, Kanijo T, Yamada K, Ibuki Y (1998) A comparative study of fixed-dose, step-down, and low dose step-up regimens of human menopausal gonadotropin for patients with polycystic ovary syndrome. Fertil Steril 70: 840–846PubMedCrossRefGoogle Scholar
  3. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 1929–1935PubMedCrossRefGoogle Scholar
  4. Bidet M, Bellanné-Chantelot C, Galand-Portier MB Tardy V, Billaud L, Laborde K, Coussieu C, Morel Y, Vaury C, Golmard JL, Claustre A, Mornet E, Chakhtoura Z, Mowszowicz I, Bachelot A, Touraine P, Kuttenn F (2009) Clincal and molecular characterization of a cohort of 161 unrelated omen with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 94: 1570–578PubMedCrossRefGoogle Scholar
  5. Bouhanna P (2003) Androgenetic alopecia: Combining medical and surgical treatments. Dermatol Surg 29: 1130–1134PubMedCrossRefGoogle Scholar
  6. Burkman RT Jr (1995) The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 98: 130S–136SPubMedCrossRefGoogle Scholar
  7. Cordera F, Grant C, van Heerden J, Thompson G, Young W (2003) Androgen- secreting adrenal tumors. Surgery 134: 874–880PubMedCrossRefGoogle Scholar
  8. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18: 774–800PubMedCrossRefGoogle Scholar
  9. Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38: 1165–1174PubMedCrossRefGoogle Scholar
  10. Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC (2003) High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod 18: 2357–2362PubMedCrossRefGoogle Scholar
  11. Eisenhardt S, Schwarzmann N, Henschel V, Germayer A, von Wolff M, Hamann A, Strowitzki T (2006) Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 91: 946–952PubMedCrossRefGoogle Scholar
  12. Elter K, Imir G, Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovary syndrome: a randomized controlled study. Hum Reprod 17: 1729–1737PubMedCrossRefGoogle Scholar
  13. EscobarMorreale HF (2010) Diagnosis and management of hirsutism. Ann NY Acad Sci 1205: 166–174CrossRefGoogle Scholar
  14. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W (2003) Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 2760–2766PubMedCrossRefGoogle Scholar
  15. Ferriman D, Gallway JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21: 1440–1447PubMedCrossRefGoogle Scholar
  16. Hardiman P, Pillay OC, Atiomo W (2003) Polycystic ovary syndrome and endometrial carcinoma. Lancet 361: 1810–1812PubMedCrossRefGoogle Scholar
  17. Hoellen F, Noack F, Ribbat J, Kelling K, Diedrich K, Bohlmann MK (2011) Androgenproduzierende Tumoren. Gynäkologische Endokrinologie 9: 109–116CrossRefGoogle Scholar
  18. Homburg R, Lambalk CB (2004) Polycystic ovary syndrome in adolescence – a therapeutic conundrum. Hum Reprod 19: 1039–1042PubMedCrossRefGoogle Scholar
  19. Hornung M, Vogel P, Schubert T, Schlitt HJ, Bolder U (2008) A case of virilization induced by a Krukenberg tumor from gastric cancer. World J Surg Oncol 6: 196Google Scholar
  20. Karimzadeh MA, Javedani M (2010) An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. Fertil Steril 94: 216–220PubMedCrossRefGoogle Scholar
  21. Ludwig M (2010) Gynäkologische Endokrinologie – Ein Handbuch für die Praxis, 1. Aufl. Optimist Fachbuchverlag HamburgGoogle Scholar
  22. Mavropoulos JC, Yancy WS, Hepburn J, Westman EC (2005) The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. Nutr Metab 2: 35CrossRefGoogle Scholar
  23. Mukherjee S, Sharma S, Chakravarty BN (2010) Comparative evaluation of pregnancy outcome in gonadotropin-clomiphene combination vs clomiphene alone in polycystic ovary syndrome and unexplained infertility – A prospective clinical trial. J Hum Reprod Sci 3: 80–84PubMedCrossRefGoogle Scholar
  24. New MI (2004) An update of congenital adrenal hyperplasia. Ann NY Acad Sci 1038: 14–43PubMedCrossRefGoogle Scholar
  25. Palomba S, Orio F, Zullo F (2006) Ovulation induction in women with polycystic ovary syndrome. Fertil Steril 86 (Suppl 1): S26-S27PubMedCrossRefGoogle Scholar
  26. Pierroz DD, Aebi AC, Huhtaniemi IT, Aubert ML (1999) Many LH peaks are needed to physiologically stimulated testosterone secretion: modulation by fasting and NPY. Am J Physiol 276: E603-E610PubMedGoogle Scholar
  27. Plewig G (2005) Akne und Rosazea. In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf W, Landthaler M (Hrsg) Dermatologie und Venerologie, Kap 61. Springer, Berlin Heidelberg New York, S 890Google Scholar
  28. Price VH (2003) Androgenetic alopecia in women. J Invest Dermatol Symp Proc 8: 24–27CrossRefGoogle Scholar
  29. Ratts VS, Pauls RN, Pinto AB, Kraja A, Williams DB, Odem RR (2007) Risk of multiple gestation after ovulation induction in polycystic ovary syndrome. J Reprod Med 52: 896–900PubMedGoogle Scholar
  30. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related ton polycystic ovary syndrome. Fertil Steril 81: 19–25Google Scholar
  31. Rushton DH (2002) Nutritional factors and hair loss. Clin Exp Dermatol 27: 396–404PubMedCrossRefGoogle Scholar
  32. Siegenthaler W, Kaufmann W, Hornborstel H, Waller HD (1992) Lehrbuch der Inneren Medizin. Thieme, Stuttgart New York, S 337–350Google Scholar
  33. Sinclair R, Wewerinke M, Jolley D (2005) Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 152: 466–473PubMedCrossRefGoogle Scholar
  34. Speiser PW, White PC (2003) Congenital adrenal hyperplasia. N. Engl J Med 349: 776–788PubMedCrossRefGoogle Scholar
  35. Stadtmauer LA, Sarhan A, Duran EH, Beydoun H, Bocca S, Pultz B, Oehringer S (2011) The impact of a gonadotropin-releasing hormone antagonist on gonadotropin ovulation induction cycles in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 95: 216: 220PubMedCrossRefGoogle Scholar
  36. Volek JS, Fernandez ML, Feinman RD, Phinney SD (2008) Dietary carbohydrate restriction induces a unique metabolic state positively affecting therogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Prog Lipid Res 47: 307–318PubMedCrossRefGoogle Scholar
  37. Witchel FS, Azziz R (2010) Nonclassic congenital adrenal hyperplasia. Int J Pediatr Endocrinol 2010: 625105. Epub 2010 Jun 30Google Scholar
  38. Wolf JE Jr, Shander D, Huber F, Jackson J, Lin CS, Mathes BM, Schrode K (2007) Randomized, double-blind clinical evaluation oft he efficiacy and safety of topical eflornithine HCl 13.9%cream in the treatment of facial hair. Int J Dermatol 46: 94–98PubMedCrossRefGoogle Scholar
  39. Wolff H (2005) Erkrankungen der Haare. In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf W, Landthaler M (Hrsg) Dermatologie und Venerologie, Kap 63. Springer, Berlin Heidelberg New York, S 943Google Scholar
  40. Young J, Tardy V, de la Perrière AB, Bachelot A, Morel Y; French Society of Endocrinology (2010) Detection and management of late-onset 21-hydroxylase deficiency in women with hyperandrogenism. Ann Endocrinol (Paris) 71 (1): 14–18CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • C. Banz-Jansen
    • 1
  1. 1.Universitätsklinikum Schleswig-Holstein Campus LübeckKlinik für Frauenheilkunde und GeburtshilfeLübeck

Personalised recommendations